ValuEngine upgraded shares of IntelliPharmaCeutics Intl (NASDAQ:IPCI) (TSE:I) from a hold rating to a buy rating in a report published on Thursday.
Separately, Zacks Investment Research upgraded IntelliPharmaCeutics Intl from a sell rating to a hold rating in a report on Tuesday, September 4th.
Shares of IPCI traded down $0.02 during trading hours on Thursday, reaching $0.56. The stock had a trading volume of 422,824 shares, compared to its average volume of 781,304. IntelliPharmaCeutics Intl has a 12 month low of $0.46 and a 12 month high of $10.50. The stock has a market capitalization of $2.46 million, a price-to-earnings ratio of -0.19 and a beta of 2.27.
IntelliPharmaCeutics International Inc, a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in Canada. It develops various drug delivery systems and a pipeline of products based on its patented Hypermatrix technology in therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain.
Recommended Story: Intrinsic Value
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for IntelliPharmaCeutics Intl Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IntelliPharmaCeutics Intl and related companies with MarketBeat.com's FREE daily email newsletter.